甘李药业：公司业务处于正常经营状态

Core Viewpoint - The company, Ganli Pharmaceutical, reported a significant increase in revenue for the first three quarters of 2025, indicating strong business performance and growth potential [1] Financial Performance - For the first three quarters of 2025, the company's revenue reached 3.047 billion yuan, an increase of 802 million yuan compared to the same period last year, representing a year-on-year growth of 35.73% [1]